Express News | Morgan Stanley's Long Position in H-Shares of Shanghai Henlius Biotech Decreases to 1.04% on Sept 3 From 5.77% - HKEX
Henlius Biotech Enhances Operations With Key Agreements
Fosun Pharma (02196.HK) subsidiary obtains pharmaceutical clinical trial approval.
Fosun Pharma (02196.HK) announced that its holding subsidiary, Shanghai Henlius Biotech, and its holding subsidiary (collectively referred to as "Henlius"), recently received approval from the National Medical Products Administration to conduct clinical trials for HLX17 (a recombinant anti-PD-1 humanized monoclonal antibody injection, hereinafter referred to as "the new drug") for the treatment of melanoma, non-small cell lung cancer, esophageal cancer, head and neck squamous cell carcinoma, colorectal cancer, hepatocellular carcinoma, triple-negative breast cancer, microsatellite instability-high or mismatch repair-deficient tumor.
Fosun Pharma: The recombinant anti-PD-1 humanized monoclonal antibody injection has been approved for clinical trials.
Fosun Pharma (600196.SH) announced that its holding subsidiary Shanghai Henlius Biotech Inc. and its...
Henlius Biotech's Cancer Drug Trial Approved
Henlius (02696.HK): The clinical trial application for the biosimilar HLX17 of the monoclonal antibody Pembrolizumab has been approved.
On September 2nd, Ganji News reported that Henlius (02696.HK) announced that its independently developed pharmaceutical HLX17 (recombinant anti-PD-1 humanized monoclonal antibody injection, also known as "HLX17") has obtained the approval of the National Medical Products Administration for clinical trial application. HLX17 is intended for the treatment of melanoma, non-small cell lung cancer, esophageal cancer, head and neck squamous cell carcinoma, colorectal cancer, hepatocellular carcinoma, biliary tract cancer, triple-negative breast cancer, microsatellite instability-high or mismatch repair-deficient tumors, and gastric cancer. HLX17 is an independently developed pharmaceutical by Henlius.
Express News | Shanghai Henlius Biotech - Clinical Trial of Pembrolizumab Biosimilar Hlx17 (Recombinant- Humanised Anti-Pd-1 Monoclonal Antibody Injection) Approved
Fosun's Management: Globalization + Innovation + Asset-light Operations for Sustained and Stable Profits
Guo Guangchang talks about innovation: The most important thing is to help users solve problems.
On August 29, 2024, Guo Guangchang, the chairman of Fosun Intl, stated at the 2024 Fosun Intl mid-term earnings conference that the core of innovation is to grasp user needs and help solve their problems. Guo Guangchang introduced that he is very proud of Fosun's four innovative platforms in the biomedical field, including Henlius, CAR-T, Da Vinci Robot, and CyberKnife. "These are world-class innovative platforms that we highly value, which can truly solve problems for customers and create value. With the good development of these four platforms, Fosun has huge potential in the field of health, and will continue to increase the investment in biomedical, and advanced medical instruments and other cutting-edge technologies."
Gelonghui announcement selection (Hong Kong stocks) | baic motor (01958.HK) achieved a net income of 6.866 billion yuan in the first half of the year.
【Today's Focus】BAIC Motor (01958.HK) achieved a net income of 6.866 billion yuan in the first half of the year. BAIC Motor (01958.HK) announced that the group's revenue decreased from 990.471 million yuan in the first half of 2023 to 943.223 million yuan in the first half of 2024, a year-on-year decrease of 4.8%, mainly due to the decrease in revenue from gasoline vehicles and electric vehicles. The group's gross profit decreased from 2.056.610 million yuan in the first half of 2023 to 1,868.680 million yuan in the first half of 2024, a year-on-year decrease of 9.1%.
Hong Kong stock announcement gold mining | PetroChina's net income attributable to shareholders in the first half of the year was 88.611 billion yuan, a year-on-year increase of 3.9%.
The main business is profitable. Kunlun Energy (00135) released its interim performance, with a net profit attributable to shareholders of 3.305 billion yuan, an increase of 2.58% year-on-year. Haitian Int'l (01882) announced its interim performance, with a net profit attributable to shareholders of approximately 1.521 billion yuan, a year-on-year increase of 23.5%.
Shanghai Henlius Biotech Records Higher Profit in H1
Henlius Biotech Experiences Strong Growth and Global Drug Approvals
Henlius (02696.HK) announces mid-term performance with a profit of approximately 0.386 billion yuan, solidifying its internationalized 'research, production, and sales integrated' capabilities.
Henlius (02696.HK) announced on August 26th that the group's total revenue for the six months ending June 30, 2024 was approximately RMB 27,461 million, mainly from drug sales, research and development services provided to customers, and licensing income, an increase of approximately RMB 2,456 million or about 9.8% compared to the six months ended June 30, 2023. For the six months ending June 30, 2024, the group's profit for the period was approximately RMB 38,630 million, compared to the six months ended June 30, 2023.
Shanghai Henlius Biotech Announces Key Management Changes
Express News | Shanghai Henlius Biotech H1 Gross Profit RMB 1,990.7 Million
Express News | Shanghai Henlius Biotech Inc - Does Not Recommend Distribution of Any Interim Dividend
Express News | Shanghai Henlius Biotech H1 Revenue RMB 2,746.1 Million
Express News | Shanghai Henlius Biotech H1 Net Income RMB 386.3 Million
HENLIUS: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024
No Data
No Data